Lynn Feun
Expertise in
30
conditions

Dr. Lynn Feun

Hematology
Umhc-Sylvester Comprehensive Cancer Center
1475 NW 12th Ave, 
Miami, FL 
Offers Telehealth
Expertise in
30
conditions
Umhc-Sylvester Comprehensive Cancer Center
1475 NW 12th Ave, 
Miami, FL 

Overview

Lynn Feun is a Hematologist in Miami, Florida. Dr. Feun is highly rated in 30 conditions, according to our data. His top areas of expertise are Melanoma, Liver Cancer, Melanoma of the Eye, and Fibrolamellar Carcinoma.

His clinical research consists of co-authoring 55 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Umhc-Sylvester Comprehensive Cancer Center
1475 NW 12th Ave, Miami, FL 33136
Other Locations
Jackson Health System
11199 Sorrento Valley Rd Ste 202, San Diego, CA 92121

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 10, 2025
Intervention Type: Drug
Study Drug: SRF388
Study Phase: Phase 1
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types
A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types
Enrollment Status: Active_not_recruiting
Publish Date: August 15, 2025
Intervention Type: Genetic
Study Phase: Phase 1
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
Phase Ib Trial of AEB071, a PKC Inhibitor, in Combination With BYL719, a PI3Kα Inhibitor, in Patients With Metastatic Uveal Melanoma
Phase Ib Trial of AEB071, a PKC Inhibitor, in Combination With BYL719, a PI3Kα Inhibitor, in Patients With Metastatic Uveal Melanoma
Enrollment Status: Completed
Publish Date: August 15, 2023
Intervention Type: Drug
Study Drugs: AEB071, BYL719
Study Phase: Phase 1
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
Enrollment Status: Completed
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: IMCgp100
Study Phase: Phase 1/Phase 2
A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)
A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)
Enrollment Status: Completed
Publish Date: January 17, 2023
Intervention Type: Biological, Drug
Study Phase: Phase 1
Phase II Study of Pembrolizumab (Keytruda®) in Advanced Hepatocellular Carcinoma (HCC)
Phase II Study of Pembrolizumab (Keytruda®) in Advanced Hepatocellular Carcinoma (HCC)
Enrollment Status: Completed
Publish Date: November 12, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

55 Total Publications

Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504.
Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers 2021, 13, 5504.
Journal: Cancers
Published: August 08, 2025
Similar Doctors
Expertise in
22
conditions
Dr. Izidore Lossos
Hematology
Expertise in
22
conditions
Dr. Izidore Lossos
Hematology

Umhc-Sylvester Comprehensive Cancer Center

1475 NW 12th Ave, 
Miami, FL 
 (0.1 miles away)
305-243-5302
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Izidore Lossos is a Hematologist in Miami, Florida. Dr. Lossos is highly rated in 22 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Marginal Zone Lymphoma (MZL), B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Transplant.

Expertise in
12
conditions
Dr. Craig Moskowitz
Hematology
Expertise in
12
conditions
Dr. Craig Moskowitz
Hematology

Umhc-Sylvester Comprehensive Cancer Center

1475 NW 12th Ave, 
Miami, FL 
 (0.1 miles away)
305-243-5302
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Craig Moskowitz is a Hematologist in Miami, Florida. Dr. Moskowitz is highly rated in 12 conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Non-Hodgkin Lymphoma.

Expertise in
23
conditions
Dr. Mikkael Sekeres
Hematology
Expertise in
23
conditions
Dr. Mikkael Sekeres
Hematology

Umhc-Sylvester Comprehensive Cancer Center

1475 NW 12th Ave, 
Miami, FL 
 (0.1 miles away)
305-243-5302
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mikkael Sekeres is a Hematologist in Miami, Florida. Dr. Sekeres is highly rated in 23 conditions, according to our data. His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Lynn Feun

How do I make an appointment with Dr. Lynn Feun?

You can book an appointment with Dr. Lynn Feun by calling their office at 305-243-4664. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lynn Feun a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lynn Feun is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lynn Feun specialize in?

While Dr. Lynn Feun is a Hematology, they have specific expertise in Melanoma, Liver Cancer, and Melanoma of the Eye. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Lynn Feun participate in research or clinical trials?

Yes. Dr. Lynn Feun has published 55 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Lynn Feun's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Lynn Feun accept my insurance?

Dr. Lynn Feun accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 305-243-4664 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Feun's expertise for a condition
ConditionClose
View All 24 Advanced Conditions
View All 42 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile